The Lynx Group
Cholangiocarcinoma News

Expert Perspective on the Evolving Standard of Care in Biliary Tract Cancers

December 2021, Vol 2, No 4

Mitesh J. Borad, MD, Mayo Clinic College of Medicine and Science, Phoenix, AZ, delivered an expert Keynote Perspective at the 3rd Annual Summit, highlighting genomic profiling as the standard of care in the management of patients with intrahepatic cholangiocarcinoma (CCA), with liquid biopsy becoming the tool of choice for genomic profiling in biliary tract cancers.

Dr Borad discussed current global approaches to CCA from a personalized medicine point of view. “The human model system is truly maybe the best place to start and end, and this would be considered bedside-to-bench research,” he said.

Integrated sequencing allows for the investigation of several aspects of disease at once and a comprehensive view of the disease, including germline analysis, therapy selection, pharmacogenomics, clonal evolution, disease prognosis, and monitoring response to therapy.

Identifying the disease driver may be done through multiplatform concordance, mutation transcript specific expression, heuristic knowledge, ranking of events, and target hyperselection. The prevalence of FGFR2 fusions in CCA is approximately 10%, almost exclusively in intrahepatic CCA. The patient-derived xenograft model can be used to identify the potential benefits and the relative efficacy of drugs, he explained.

“Working with colleagues in the radiation department, we have been trying to identify mutation signatures, using Fourier transform–based methods, what we would call radiomics, machine learning, or artificial intelligence, to see if we could identify those patients, or at least enrich very quickly, so we know if we have a patient with an FGFR2 fusion on our hands or not,” said Dr Borad. “And you can apply the same understanding to other mutations, such as IDH1/2 or KRAS.”

When we manage driver mutations with drugs such as pemigatinib, tumor shrinkage has been seen in up to 80% of cases. These responses have been semidurable, so the current unmet need is how to keep these responses durable, or how to overcome resistance, Dr Borad said.

He explained that tumor evolution is clearly common, and oncologists have to analyze it comprehensively and often to stay on top of the treatment. Whole-genome sequencing and other “omics” assessment should also be done; however, cost is a limitation. The analysis should be done at every decision point. As an initial step toward adopting this approach, comprehensive analysis may be completed at the initial diagnosis, but the compromise may be somewhere in the middle.

The ERRFI1 gene (or MIG-6) is a regulator of multiple pathways, such as EGFR or MET. Treating patients with erlotinib led to reduced tumor volume at 3 months.

Microsatellite instability-high is a targetable biomarker, with highly durable response rates after treatment in solid tumors. Mutational burden is variable across biliary tract cancers. Very deep and durable responses have been seen in patients with mismatch repair-deficient (dMMR) who received PD-1 blockade therapy. However, some patients do not respond to this therapy. “Studying these heterogeneities will be key to our understanding of how we approach these problems,” said Dr Borad.

Liquid biopsy may be used for target (or biomarker) identification, prognostication, dMMR detection, and response assessment in the next year or two. The benefits of liquid biopsy include speed, minimal invasiveness, ability to complete serial analysis without harm, possible improved representation of tumor heterogeneity, and it may be used to detect early resistance to therapy.

How can we select therapy better to increase the likelihood of response? Dr Borad suggested that tumor organoids and ex vivo therapy models may be incorporated for clinical decision enhancement as predictive tools.

Related Items

A Global Perspective on CCA
By Virote Sriuranpong, MD, PhD
Videos
Dr Virote Sriuranpong provides a perspective on key issues facing Thailand and other Asian countries in the prevention, screening, and early diagnosis of CCA.
Molecular Targets in iCCA Surgical Candidates
By Keri Lunsford, MD, PhD, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Videos
Drs Keri Lunsford and Alice Wei provide their perspectives on how the molecular profile of iCCA patients can help direct surgery and locoregional therapy.
Periadjuvant Therapy in iCCA
By Cristina Ferrone, MD; Shishir Kumar Maithel, MD, FACS
Videos
Dr Cristina Ferrone discusses the use of adjuvant therapy, and Dr Shishir Kumar Maithel speaks to the role of neoadjuvant therapy in patients with iCCA.
New Frontiers in Surgery for CCA
By Skye Mayo, MD, MPH, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Videos
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Transplantation in iCCA
By Keri Lunsford, MD, PhD, FACS; Maria B. Majella Doyle, MD, MBA, FRCSI, FACS
Videos
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
New Pathways and Molecular Targets in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Potential therapeutic targets for cholangiocarcinoma (CCA) include oncogenic pathways and other options, such as epigenetics, posttranslational modifications, and metabolism, according to presentations delivered during Session I, “Advances in Translational/Molecular Targets in CCA: New Molecular Targets/Pathways in CCA,” at the 3rd Annual CCA Summit.
Molecular Epidemiology of Cholangiocarcinoma: Identifying New Inherited Variants
By Erin Burns, PhD
December 2021, Vol 2, No 4
Cholangiocarcinoma (CCA) involves genetic heterogeneity, highlighting the need to identify new inherited variants, as discussed at the 3rd Annual CCA Summit in Session II, “Molecular Epidemiology of CCA.”
The Future of Chemotherapy in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Personalization of therapy and novel regimens are needed to improve options for patients with cholangiocarcinoma (CCA).
Understanding Predictive Biomarkers and Resistance to Immunotherapy in Biliary Tract Cancers
By Erin Burns, PhD
December 2021, Vol 2, No 4
Improved understanding of predictive biomarkers is needed in immuno-oncology, and various immunotherapy combinations using different mechanisms of action are being investigated in cholangiocarcinoma (CCA) and other biliary tract cancers, according to presentations delivered at Session IV, “What’s New in Immuno-­oncology in BTC? Monotherapy and Combo Therapies,” at the 3rd Annual CCA Summit.
Biomarker Testing and Imaging in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
New biomarker technologies may be combined with cholangiocarcinoma (CCA) characteristics to predict patient response to treatment, according to presenters at Session V, “Biomarker Testing in CCA: New Technologies/­Imaging as a Biomarker,” during the 3rd Annual CCA Summit.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: